Eton Pharmaceuticals filings document a rare-disease pharmaceutical business built around approved products, licensed commercialization rights and late-stage product candidates. Recent 8-K reports cover DESMODA FDA approval for central diabetes insipidus, the HEMANGEOL U.S. rights acquisition and launch, ET-700 clinical study disclosure for Wilson disease, and quarterly and annual financial results that include GAAP and non-GAAP measures.
The filing record also includes credit-agreement amendments, direct financial obligation disclosures, executive appointment and compensation matters, and definitive proxy materials covering executive compensation, equity awards and governance matters. These filings tie product portfolio changes, financing terms, capital structure and corporate governance to Eton's public-company reporting.
Eton Pharmaceuticals reported a profitable quarter for the three months ended March 31, 2026, with total revenues of $24,266 and net income of $1,554, compared with a net loss a year earlier. Revenue was driven by higher product sales and royalties, especially from INCRELEX®, GALZIN®, ALKINDI SPRINKLE®, Carglumic Acid and the addition of KHINDIVI™. Licensing revenue declined because the prior year included one-time INCRELEX® out-licensing and DS-200 milestone payments. Gross profit rose to $14,735 as product sales expanded, while operating expenses increased mainly from higher FDA fees and headcount.
Cash from operating activities strengthened to $7,405, but overall cash declined to $19,661 after $15,075 of investing outflows, largely a $14,000 upfront payment for U.S. rights to HEMANGEOL® and a $1,000 IPR&D license. The balance sheet shows $97,710 in total assets, including $43,738 of intangible assets related to acquired rare disease products, and $30,747 of SWK term debt. Management highlighted non-GAAP adjusted EBITDA of $5,709 and non-GAAP net income of $4,482, reflecting add-backs for amortization, stock-based compensation and inventory step-up.
Eton Pharmaceuticals reported strong first-quarter 2026 results, with total net revenue of $24.3 million, up 40% from $17.3 million a year earlier, and product sales and royalties rising 73% to $24.3 million. Gross profit increased to $14.7 million from $9.9 million.
The company generated Adjusted EBITDA of $5.7 million, or 24% of revenue, versus $3.7 million and 21% a year ago. GAAP results swung to net income of $1.6 million from a $1.6 million loss, while non-GAAP net income rose to $4.5 million. Eton raised its 2026 revenue outlook to more than $120 million and now targets at least a 30% Adjusted EBITDA margin, supported by record product sales, launches of DESMODA and HEMANGEOL, and continued rare-disease pipeline progress.
Eton Pharmaceuticals filed a report describing the relaunch of HEMANGEOL (propranolol) Oral Solution, the only FDA‑approved treatment for infantile hemangioma, a rare pediatric vascular tumor that can be time‑sensitive.
The relaunch integrates the full Eton Cares patient support program, including $0 co‑pay for eligible commercially insured patients and expanded patient assistance. HEMANGEOL is an orphan drug typically started between five weeks and five months of age and used for about six months to help prevent complications. The company estimates approximately 5,000–10,000 infants in the United States are treated with HEMANGEOL each year and is using an exclusive rare disease specialty pharmacy distribution model to support timely access.
Eton Pharmaceuticals filed an 8-K to announce dosing of the first patient in a pilot clinical study of ET-700, its extended-release zinc acetate candidate for Wilson disease. The double-blinded, placebo-controlled trial in Denmark will follow 36 healthy volunteers over four weeks using 64Cu PET imaging to measure intestinal copper absorption.
The study compares GALZIN 50 mg three times daily, ET-700 75 mg twice daily plus one placebo dose, and placebo three times daily, with hepatic 64Cu uptake as the primary endpoint. Eton’s CEO said that, if approved, ET-700 could potentially exceed $100 million in peak annual U.S. sales and support simpler dosing for this lifelong condition.
Eton Pharmaceuticals is holding its 2026 annual stockholders meeting virtually on June 9, 2026 at 10:00 a.m. CDT. Stockholders of record as of April 10, 2026, when 27,359,791 common shares were outstanding, can vote.
Investors are being asked to elect Jenn Adams and Charles J. Casamento as Class II directors through the 2029 meeting and to ratify Grant Thornton LLP as independent auditor for the year ending December 31, 2026. The proxy describes Eton’s staggered, largely independent board, committee structure, executive team, and pay programs, including performance-based bonuses and equity awards, along with detailed director and executive compensation and significant stockholder ownership.
Eton Pharmaceuticals director Norbert G. Riedel reported option exercises that increased his common stock holdings. On April 21, 2026, he exercised employee stock options to acquire 19,655 shares of common stock at $8.61 per share and 12,500 shares at $7.31 per share, for a total of 32,155 shares. After these transactions, he directly owns 67,155 common shares and also has 157,145 common shares held indirectly through the “Norbert G. Riedel 2002 Trust, Loan Thi Tran 2002 Trust” family trust, where he serves as trustee.
Eton Pharmaceuticals announced a planned chief financial officer transition. Judith “Judy” Matthews has been appointed Executive Vice President, Accounting and Finance and will become Chief Financial Officer, Corporate Secretary, and Treasurer effective June 1, 2026, succeeding James Gruber. Gruber will remain CFO through May 31, 2026 and then serve under a six-month consulting agreement to support continuity.
Matthews’ compensation includes an annual base salary of $440,000, plus an annual discretionary bonus targeted at 45% of base salary, tied to corporate and/or individual performance goals approved by the board. As an inducement, she received a one-time option to purchase 37,000 shares of common stock, vesting in equal annual installments over four years, and will participate in standard executive benefit plans. The company states her selection was not made pursuant to any arrangement with another person and notes no disclosable family or related-party relationships.
Eton Pharmaceuticals entered into a sixth amendment to its credit agreement with SWK Funding LLC. The amendment lowers the loan’s interest rate from Secured Overnight Financing Rate (SOFR) plus 6.75% to SOFR plus 6.55% and reduces the SOFR floor from 5.0% to 2.75%.
The interest-only period was extended to November 2026, and Eton may choose to begin principal payments in May 2026 or defer them until November 2026. No fees were paid to SWK in connection with this amendment, and the loan’s maturity date remains in December 2027.
Eton Pharmaceuticals Inc: The Vanguard Group filed an amendment to a Schedule 13G reporting beneficial ownership of 0 shares (0%) of Common Stock following an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538, effective after the January 12, 2026 realignment.
Eton Pharmaceuticals is a Delaware-based rare disease drug company with a market value of about $360.6 million held by non‑affiliates as of June 30, 2025 and 27,284,491 common shares outstanding as of March 17, 2026. It commercializes eight U.S. rare disease products, including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone.
The pipeline includes five late-stage candidates: ET‑600 for diabetes insipidus with a PDUFA goal date of February 25, 2026, Amglidia for neonatal diabetes, ET‑700 for Wilson disease, ET‑800 for adrenal insufficiency and a ZENEO hydrocortisone autoinjector for adrenal crisis. Eton relies on third‑party manufacturers, the FDA’s 505(b)(2) and 505(j) pathways, and maintains patents on key assets extending into the 2030s and 2040s.
The company highlights exposure to U.S. pricing reforms such as the Inflation Reduction Act, government rebate and discount programs, PBM and formulary pressure, global price controls, cybersecurity and AI data risks, counterfeit products, product liability, and strong competition in rare endocrine and metabolic markets.